Wednesday, July 26, 2017 4:15:36 PM
Oxford Biomedica has the ability to deliver the next blockbuster, how to deliver virus to T-cells in the patient directly without the need for isolating, transforming and amplifying the cells ex-vivo.
the interests of Vulpes investors and indeed all shareholders, will be protected against the threat of either unwise dilution or indeed, the threat of a takeover approach at an unreasonably low valuation. Given OXB’s unmatched gene therapy and lentivector expertise and it’s very strong patent protected IP for gene therapy manufacturing, we see OXB has a very attractive target for acquisition in a world with a growing shortage of biologics manufacturing.
HTTP://www.vulpesinvest.com/wp-content/uploads/2017/07/VLSF%20Special%20Report_Oxford%20BioMedica%20_July_2017.pdf
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM